SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Senior who wrote (77739)7/11/2025 8:04:13 PM
From: Ccube  Read Replies (1) of 78480
 
CAPR
might be worth a long shot. seems to be the current leader in the field according the Chatgpt
close to 52week low on the FDA news.

"?? Mechanism of Action of Deramiocel (CAP-1002) 1. What Is Deramiocel? Deramiocel is composed of allogeneic cardiosphere-derived cells (CDCs) — a type of stem-like cell originally isolated from heart tissue. These cells are not intended to engraft or replace tissue, but rather to act as cellular modulators of inflammation and fibrosis through paracrine effects.
"

?? Summary Table: Exosome/Paracrine-Based Therapies in DMD

CompanyTherapy & StatusModalityFocus Area
CapricorDeramiocel (CAP-1002), Phase IIICDC-derived exosomesCardiomyopathy + muscle
ENCell Co.EN001, Phase I completedMSC-based paracrine cellsMuscle regeneration
AposcienceAPOSEC™, secretome/exosome productCell-free exosome mixWound healing (platform)
Others (70+)Many exosome-focused platformsExosome therapiesBroad regenerative fields


? Takeaway
  • Capricor is the current leader with DMD-specific exosome therapy, most advanced in clinical development.

  • ENCell and Aposcience are applying similar modalities with distinct sources and indications.

  • While 70+ exosome companies exist, few focus squarely on DMD yet—most are in early/regenerative stages.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News